Reckitt Benckiser CEO Rakesh Kapoor has a weakness for scribbling charts in meetings. A particular favorite of Kapoor shows the impact of consumer spending power on sales of the company’s homecare products.
While revenue keeps pace for a while with a rise in employment and wages, there is a point where the line flattens. There are only so many Air Wick room fresheners or tubs of Vanish stain-remover that one person can use.
By contrast, his line showing the effect of higher spending power on sales of consumer healthcare products — such as Reckitt’s Nurofen and Mucinex — just keeps rising, demonstrating something Kapoor describes as the “infinite potential” of this particular category of goods.
That is why he is interested in buying Pfizer’s consumer healthcare business (which makes Advil and Chapstick) if and when it comes up for sale, as reported by Bloomberg News. An aging population with an appetite for over-the-counter pills, vitamins and hemorrhoid cream is a lucrative prospect.
The interest in a large-scale merger and acquisition is also a tacit recognition that while the performance of Reckitt’s existing healthcare business has been stellar, homecare has been a bit flat: like that line on the chart. While it is hard to be too critical of a company with an industry-beating 24.5 percent operating margin last year, healthcare looks more likely to sustain that over the long term.
The homecare business did rally somewhat in the third quarter, with like-for-like sales up 5 percent, but it remains to be seen whether that continued for the rest of the year. Healthcare sales have increased at a steady clip of 13 or 14 percent year-on-year for every quarter this year.
Kapoor’s problem is that many of the best consumer healthcare brands are locked up in big pharmaceutical companies, part of the reason why the top 10 suppliers account for just 30 percent of the market. GlaxoSmithKline’s consumer joint venture with Novartis is another business that Reckitt eyes covetously.
Yet even if its patience pays off and Pfizer or GSK put the businesses on the block, there is nothing to suggest they will be cheap. To his credit, Kapoor pulled out of the bidding last year for Merck & Co’s consumer division. That was sold to Bayer at an eye-watering 7.5 times sales. Deborah Aitken of Bloomberg Intelligence says the expected norm for this type of deal would be about 5 times sales. Based on last year’s sales of US$3.4 billion, that would value Pfizer’s consumer business at US$17 billion.
There is no pressure on Kapoor to hurry a deal and there is an acknowledgement that the Pfizer assets may not become available for a couple of years. Reckitt has been strengthened by the relative weakness of US competitor Procter & Gamble, which has been locked in its own battle to revive growth.
KEEPING UP: The acquisition of a cleanroom in Taiwan would enable Micron to increase production in a market where demand continues to outpace supply, a Micron official said Micron Technology Inc has signed a letter of intent to buy a fabrication site in Taiwan from Powerchip Semiconductor Manufacturing Corp (力積電) for US$1.8 billion to expand its production of memory chips. Micron would take control of the P5 site in Miaoli County’s Tongluo Township (銅鑼) and plans to ramp up DRAM production in phases after the transaction closes in the second quarter, the company said in a statement on Saturday. The acquisition includes an existing 12 inch fab cleanroom of 27,871m2 and would further position Micron to address growing global demand for memory solutions, the company said. Micron expects the transaction to
Vincent Wei led fellow Singaporean farmers around an empty Malaysian plot, laying out plans for a greenhouse and rows of leafy vegetables. What he pitched was not just space for crops, but a lifeline for growers struggling to make ends meet in a city-state with high prices and little vacant land. The future agriculture hub is part of a joint special economic zone launched last year by the two neighbors, expected to cost US$123 million and produce 10,000 tonnes of fresh produce annually. It is attracting Singaporean farmers with promises of cheaper land, labor and energy just over the border.
US actor Matthew McConaughey has filed recordings of his image and voice with US patent authorities to protect them from unauthorized usage by artificial intelligence (AI) platforms, a representative said earlier this week. Several video clips and audio recordings were registered by the commercial arm of the Just Keep Livin’ Foundation, a non-profit created by the Oscar-winning actor and his wife, Camila, according to the US Patent and Trademark Office database. Many artists are increasingly concerned about the uncontrolled use of their image via generative AI since the rollout of ChatGPT and other AI-powered tools. Several US states have adopted
A proposed billionaires’ tax in California has ignited a political uproar in Silicon Valley, with tech titans threatening to leave the state while California Governor Gavin Newsom of the Democratic Party maneuvers to defeat a levy that he fears would lead to an exodus of wealth. A technology mecca, California has more billionaires than any other US state — a few hundred, by some estimates. About half its personal income tax revenue, a financial backbone in the nearly US$350 billion budget, comes from the top 1 percent of earners. A large healthcare union is attempting to place a proposal before
RSS